Drug intelligence / Profile preview

DWP DE-2302

Development stage: Unknown
Lead developer: Daewoo Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

DWP DE-2302 is an investigational ophthalmic drug candidate developed by Daewoo Pharma for the treatment of glaucoma. Currently in Phase 2 clinical development, the drug is intended to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. While the specific active pharmaceutical ingredients and molecular targets have not been publicly disclosed, DWP DE-2302 is a key component of Daewoo Pharma's specialized ophthalmic R&D pipeline, which focuses on addressing various ocular conditions through improved formulations and therapeutic combinations.

Beyond the preview

Go deeper on DWP DE-2302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWP DE-2302.

Explore the full profile